Source:http://linkedlifedata.com/resource/pubmed/id/20211331
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-3-9
|
| pubmed:abstractText |
Abnormal matrix metalloproteinase (MMP) activity and diastolic dysfunction may affect left ventricular (LV) remodeling and prognosis, but it is not known whether the combined evaluation of MMP-3 and MMP-9 and variables of diastolic dysfunction are useful for the risk stratification of patients with systolic heart failure (HF). Therefore, this study was designed to assess the value of combining circulating levels of MMPs and tissue Doppler measures of LV diastolic dysfunction to risk-stratify patients with systolic HF. Consecutive patients with systolic HF due to either ischemic or nonischemic cardiomyopathy (n = 134) and LV ejection fractions <45% were submitted to complete echocardiographic and Doppler examinations. The ratio of mitral E peak velocity and averaged e' velocity (E/e') was calculated. Plasma levels of MMP-3 and MMP-9 were measured at the time of index echocardiography. All-cause mortality was defined as the end point. The mean LV ejection fraction was 28 +/- 9%. There was a total of 32 deaths during follow-up (24 +/- 14 months). Several clinical, biochemical, Doppler, and echocardiographic parameters were associated with the outcome on univariate Cox regression analysis. After statistical adjustment for the potentially confounding factors by multivariate analysis, E/e' (hazard ratio 1.11, p = 0.0028), ejection fraction (hazard ratio 0.92, p = 0.017), and MMP-9 (hazard ratio 1.01, p = 0.027) remained significant independent predictors of the end point. Kaplan-Meier curves showed that survival was worse in patients with E/e' ratios >/=13 and MMP-9 levels >89.9 ng/mL (p <0.0001). In conclusion, the assessment of circulating MMP levels and tissue Doppler measures of LV diastolic dysfunction may improve the prognostic stratification of patients with systolic HF.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1879-1913
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2010 Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
105
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
853-6
|
| pubmed:meshHeading |
pubmed-meshheading:20211331-Aged, 80 and over,
pubmed-meshheading:20211331-Diastole,
pubmed-meshheading:20211331-Echocardiography, Doppler, Pulsed,
pubmed-meshheading:20211331-Female,
pubmed-meshheading:20211331-Heart Failure, Systolic,
pubmed-meshheading:20211331-Humans,
pubmed-meshheading:20211331-Male,
pubmed-meshheading:20211331-Matrix Metalloproteinase 3,
pubmed-meshheading:20211331-Matrix Metalloproteinase 9,
pubmed-meshheading:20211331-Prognosis,
pubmed-meshheading:20211331-Risk Assessment,
pubmed-meshheading:20211331-Ventricular Dysfunction, Left
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure.
|
| pubmed:affiliation |
Internal Medicine Department, University of Pisa, Pisa, Italy.
|
| pubmed:publicationType |
Journal Article
|